A detailed history of Advantage Alpha Capital Partners LP transactions in Vericel Corp stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 14,823 shares of VCEL stock, worth $837,499. This represents 0.15% of its overall portfolio holdings.

Number of Shares
14,823
Previous 22,611 34.44%
Holding current value
$837,499
Previous $1.04 Million 39.63%
% of portfolio
0.15%
Previous 0.24%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$42.25 - $53.56 $329,043 - $417,125
-7,788 Reduced 34.44%
14,823 $626,000
Q2 2024

Aug 13, 2024

SELL
$41.71 - $52.9 $99,144 - $125,743
-2,377 Reduced 9.51%
22,611 $1.04 Million
Q1 2024

May 13, 2024

SELL
$32.52 - $52.33 $289,037 - $465,109
-8,888 Reduced 26.24%
24,988 $1.3 Million
Q4 2023

Feb 13, 2024

BUY
$30.85 - $37.09 $1.05 Million - $1.26 Million
33,876 New
33,876 $1.21 Million

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.67B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track Advantage Alpha Capital Partners LP Portfolio

Follow Advantage Alpha Capital Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advantage Alpha Capital Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Advantage Alpha Capital Partners LP with notifications on news.